Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Exelixis Inc (EXEL)

Exelixis Inc (EXEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,812,905
  • Shares Outstanding, K 303,200
  • Annual Sales, $ 1,830 M
  • Annual Income, $ 207,770 K
  • 60-Month Beta 0.56
  • Price/Sales 3.73
  • Price/Cash Flow 29.26
  • Price/Book 3.08
Trade EXEL with:

Options Overview Details

View History
  • Implied Volatility 44.36% ( +2.86%)
  • Historical Volatility 20.40%
  • IV Percentile 78%
  • IV Rank 50.41%
  • IV High 67.22% on 06/17/24
  • IV Low 21.12% on 08/30/23
  • Put/Call Vol Ratio 0.18
  • Today's Volume 3,707
  • Volume Avg (30-Day) 1,551
  • Put/Call OI Ratio 0.69
  • Today's Open Interest 55,862
  • Open Int (30-Day) 65,050

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 0.31
  • Number of Estimates 9
  • High Estimate 0.42
  • Low Estimate 0.27
  • Prior Year 0.25
  • Growth Rate Est. (year over year) +24.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.36 +4.35%
on 06/20/24
22.58 -1.31%
on 06/27/24
+0.60 (+2.77%)
since 05/31/24
3-Month
20.14 +10.68%
on 05/29/24
23.95 -6.95%
on 04/04/24
-1.39 (-5.87%)
since 04/01/24
52-Week
18.64 +19.58%
on 10/23/23
24.34 -8.42%
on 01/02/24
+3.18 (+16.64%)
since 06/30/23

Most Recent Stories

More News
Cancer Rates Surge: Key Biotech Stocks Leading the Charge in Oncology Drug Development

USA News Group News Commentary – According to the American Cancer Society, 2024 will be the first year the USA expects to have more than 2 million new cancer cases. In order to respond to the rising...

ONCY : 0.9950 (+0.51%)
ONC.TO : 1.35 (-2.17%)
GSK : 38.66 (+0.42%)
GH : 29.24 (+1.25%)
EXEL : 22.61 (+0.62%)
GILD : 69.31 (+1.02%)
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?

These stocks are both experts in their respective fields.

PFE : 28.24 (+0.93%)
NVO : 144.38 (+1.15%)
EXEL : 22.61 (+0.62%)
Exelixis (EXEL) Q1 2024 Earnings Call Transcript

EXEL earnings call for the period ending March 31, 2024.

EXEL : 22.61 (+0.62%)
Exelixis: Q1 Earnings Snapshot

Exelixis: Q1 Earnings Snapshot

EXEL : 22.61 (+0.62%)
4 Magnificent Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market

Phenomenal deals can still be found, even with the Nasdaq Composite climbing to a new all-time high.

COMP : 3.57 (-0.83%)
$NASX : 17,732.60 (-0.71%)
META : 504.34 (+0.02%)
EXEL : 22.61 (+0.62%)
S : 20.72 (-1.57%)
PINS : 43.84 (-0.52%)
2 Biotech Stocks to Buy Hand Over Fist in March

These stocks are worth buying in most months of the year.

REGN : 1,049.04 (-0.19%)
EXEL : 22.61 (+0.62%)
4 Thrilling Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market

The growth-driven Nasdaq Composite has entered a new bull market, but plain-as-day deals can still be found.

COMP : 3.57 (-0.83%)
$NASX : 17,732.60 (-0.71%)
MA : 440.77 (-0.09%)
PUBM : 20.07 (-1.18%)
EXEL : 22.61 (+0.62%)
AMZN : 193.95 (+0.36%)
2 Stocks Under $30 to Buy and Hold

You don't need to be a millionaire to get started. Investing on a budget can work, too.

ADYEY : 11.8700 (-1.49%)
EXEL : 22.61 (+0.62%)
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END

ONCY : 0.9950 (+0.51%)
ONC.TO : 1.35 (-2.17%)
EXEL : 22.61 (+0.62%)
PFE : 28.24 (+0.93%)
BTAI : 1.3100 (+2.34%)
BMY : 41.85 (+0.77%)
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

ONCY : 0.9950 (+0.51%)
ONC.TO : 1.35 (-2.17%)
EXEL : 22.61 (+0.62%)
PFE : 28.24 (+0.93%)
BTAI : 1.3100 (+2.34%)
BMY : 41.85 (+0.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the...

See More

Key Turning Points

3rd Resistance Point 22.84
2nd Resistance Point 22.71
1st Resistance Point 22.59
Last Price 22.65
1st Support Level 22.34
2nd Support Level 22.21
3rd Support Level 22.09

See More

52-Week High 24.34
Last Price 22.65
Fibonacci 61.8% 22.16
Fibonacci 50% 21.49
Fibonacci 38.2% 20.82
52-Week Low 18.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar